Search
MediciNova Inc
MNOVAdd to Watchlist
1.330USD
-0.010-0.75%
Close 07-31 16:00（ET）Quotes delayed by 15 min
65.46MMarket Cap
LossP/E TTM
More Details of MediciNova Inc Company
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
MediciNova Inc Info
Ticker SymbolMNOV
Company nameMediciNova Inc
IPO dateDec 01, 2006
CEOIwaki (Yuichi)
Number of employees13
Security typeOrdinary Share
Fiscal year-endDec 01
Address4275 Executive Square
CityLA JOLLA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92037
Phone18583731500
Websitehttps://medicinova.com/
Ticker SymbolMNOV
IPO dateDec 01, 2006
CEOIwaki (Yuichi)
Company Executives of MediciNova Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Jason J. Kruger
Mr. Jason J. Kruger
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Jason J. Kruger
Mr. Jason J. Kruger
Chief Financial Officer
Chief Financial Officer
--
--
FAQs
Who are the top five shareholders of MediciNova Inc?
The top five shareholders of MediciNova Inc are: Dr. Yuichi Iwaki, M.D., Ph.D.
How many institutions hold shares of MediciNova Inc (MNOV)?
As of 2026Q1, 66 institutions hold shares of MediciNova Inc, with a combined market value of approximately 6.15M, accounting for 12.50% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 687606.00.